Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials
Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials. // Obesity Pillars. – URL: https://www.sciencedirect.com/science/article/pii/S2667368126000574?dgcid=rss_sd_all
Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials. Obesity Pillars. https://www.sciencedirect.com/science/article/pii/S2667368126000574?dgcid=rss_sd_all
“Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.” Obesity Pillars.
@article{article94827,
title = {Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials},
journal = {Obesity Pillars},
url = {https://www.sciencedirect.com/science/article/pii/S2667368126000574?dgcid=rss_sd_all}
}
European Journal of Clinical Nutrition, Published online: 20 November 2026; doi:10.1038/s41430-026-01857-5 Cyanocobalamin supplementation strategies in patients with Crohn’s disease and terminal ileal resection in clinical practice
European Journal of Clinical Nutrition, Published online: 20 November 2026; doi:10.1038/s41430-026-01855-7 Association of Mediterranean–DASH intervention for neurodegenerative delay (MIND) diet with cognition and total and...
ABSTRACT Food and land systems in the United Kingdom face growing challenges from climate change, biodiversity loss, and ongoing uncertainty regarding transitions to Net Zero. Nature‐based Solutions (NbS) offer a promising way to...